The pharmacokinetics of a single 2.0-g intravenous dose of cefpiramide in patients with normal or impaired renal function were studied. Serial concentrations in serum and urine were measured by using highperformance liquid chromatography, and the effect of the concentration in serum on protein binding was assessed. Thirty patients (ten with creatinine clearances of >80 mi/min, ten with creatinine clearances between 10 and 80 ml/min, and ten on dialysis) were studied. The concentration-time curve of cefpiramide was best described by an open two-compartment model. The elimination half-lives in patients with normal or impaired renal function or those on dialysis were 5.41 ± 1.44, 8.3 ± 2.82, and 8.38 ± 4.06 h, respectively, and the serum clearances in the same groups were 2.0 ± 0.84, 1.29 ± 0.45, and 2.04 ± 1.10 liters/h, respectively. There were no significant differences in any of the parameters among the three groups of patients. In patients with normal or impaired renal function, protein binding varied between 93.0 ± 1.3% at 304.4 ,ug/ml and 99.3 ± 0.8% at 41.1 ,ug/ml and was linearly and inversely related to the cefpiraniide concentration in serum. In patients on dialysis, protein binding was significantly lower (P < 0.05) and varied between 88.5 ± 7.1% at 173.4 ,ug/ml to 94.9 ± 4.8% at 46.8 ,ug/ml. In patients with normal or abnormal renal function, renal cefpiramide clearance decreased linearly with declining renal function, whereas plasma clearance was maintained. Therefore, nonrenal elimination becomes more important as renal impairment progresses.
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Cefpiramide is an investigational cephalosporin with broad-spectrum in vitro antibacterial activity (1, 4, 8) .
It is highly protein bound (96.3% at 100 pg/ml) and has a reported half-life of 4.4 h in volunteers with normal renal function (6, 7) . High and prolonged concentrations in blood are achieved after intravenous infusion.
The purpose of this study was to define further the pharmacokinetics of cefpiramide in patients with normal or impaired renal function and determine the effect of the concentration of the antibiotic on its binding to serum proteins.
MATERIALS AND METHODS
Written informed consent was obtained from all subjects. Sixteen subjects were men, and fourteen were women. The subjects ranged in age from 18 to 62 years, with a mean of 42 years. Individuals with stable renal function were recruited according to the following categories: group 1 (10 volunteers), normal renal function and creatinine clearance (CLCR) of -90 ml/min; group 2 (10 volunteers), impaired renal function subcategorized as follows: group 2a (mild), 50 -CLCR < 70 ml/min; group 2b (moderate), 30 < CLCR < 50 ml/min; group 2c (severe), 10 < CLCR < 30 ml/min; group 3 (10 volunteers), individuals requiring chronic hemodialysis. Subjects from group 3 were studied on interdialysis days. CLCR measurements were made in all patients within 2 weeks and in most within a few days of the study. There were no significant differences when the three groups of subjects were high-performance liquid chromatography. Urine specimens were collected before drug iifusion and from 0 to 2, 2 to 4, 4 to 8, 8 to 12, 12 to 24, and 24 to 48 h after initiation of the infusion. Urine specimens were placed immediately on ice and then frozen at -700C until assay.
Our method of high-performance liquid chromatography and its performance specifications for the determination of cefpiramide in serum and urine have been previously reported (3). Preinfusion serum and urine specimens were included in all runs.
Pharmacokinetic and statistical analyses. The data were fit to a one-, two-, and three-compartment intravenous infusion model, and the Schwartz (11) and Leonard (T. Leonard, MRC Technical Report, University of Wisconsin, Madison, 1979) criteria for each were calculated. On the basis of this analysis, a two-compartment model, as previously reported (7), best represented the data. The following parameters, among others (see Tables 1 and 2 The serum samples were prepared as follows. After adjustment of the pH of the serum to 7.4 by bubbling C02, the serum was incubated at 37°C for 30 min. Serum (1 ml) was then pipetted into two Centrifree tubes and incubated for an additional 15 min at 37°C. The tubes were then centrifuged at 1,000 x g for 10 min at 37°C. Internal standard solution (1 ml), as described above, was then added to 0. 
RESULTS
The mean peak cefpiramide concentrations (± standard deviation) and concentrations at 12 and 24 h in the three groups were: group 1, 307 ± 32.9, 22.2 ± 12.9, 5.8 ± 5.0; group 2, 316 ± 58, 37.3 ± 19.8, 14.3 ± 12.0; group 3, 254 ± 56.0, 29.4 ± 24.6, 9.6 ± 13.4 ,ug/ml, respectively.
The concentration-time curves for a patient with normal renal function and for a dialysis patient are depicted in Fig.  1 and 2. They are virtually superimposable, demonstrating that renal impairment has little or no effect on the elimination of cefpiramide.
The pharmacokinetic parameters in subjects with normal renal futiction are similar to those previously reported (Table 1) (7). All of the parameters (Table 1) , including the terminal half-life, were poorly correlated (V1, r = 0.271; Ex2, r = -0.012; t1i2, r = -0.033; CL, r = -0.089) with CLCR. When the three groups were compared, the mean elimination half-lives (P > 0.05) and plasma clearances (P > 0.05) of total drug were not significantly different. With the exception of the apparent volume of distribution, none of the other parameters was significantly different (P > 0.05) when the three groups were compared. Cefpiramide renal excretion is summarized in Table 2 .
Renal clearance declined linearly (r = 0.81, slope = 0.05, P = 0.0001) with decreasing CLCR (Fig. 3) , whereas total drug plasma clearance remained unchanged (r = 0.06, slope = 0.02, P = 0.768) (Fig. 4) . Thus, nonrenal mechanisms of excretion become increasingly important as renal function declines.
Protein binding ( (9) . Whether this high degree of protein binding will interfere with its antibacterial activity, as has been described for cefonicid (2) , requires further investigation. 
